IP Library Granted Patent US 11,020,360
Granted Patent B2
US 11,020,360 · App. 16/857,520 · Granted Jun 1, 2021

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Inventors: Xianqi Kong (Dollard-des-Ormeaux, CA); Mohamed Atfani (Laval, CA); Benoit Bachand (Saint-Laurent, CA); Abderrahim Bouzide (Laval, CA); Stephane Ciblat (Montreal, CA); Sophie Levesque (Mirabel, CA); David Migneault (Laval, CA); Isabelle Valade (Laval, CA); Xinfu Wu (Laval, CA); Daniel Delorme (Saint-Lazare, CA)
Assignee: Bellus Health Inc.
A61K31/145A61K47/54A61K47/542A61K47/545A61K47/549A61K47/554A61K47/64C07C309/15C07C309/18C07C309/19C07C309/24C07D207/16C07D209/20C07D217/24C07D233/64C07D285/36C07D285/38C07D291/02C07D317/40C07D323/02C07D333/24C07H7/02C07H15/12C07J9/005C07K5/0606C07K5/06026C07K5/06052C07K5/06069C07K5/06086C07K5/081C07K5/0806C12P11/00C12P13/001Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,020,360
App. No.
16/857,520
Granted
Jun 1, 2021
Kind
B2
Abstract

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Claims (13)

1. A compound of Formula IV, or a pharmaceutically acceptable salt thereof:

wherein:

aa 1 is valine, lysine, serine, alanine, isoleucine, histidine, or O-benzylserine;

aa 2 is valine, lysine, serine, alanine, isoleucine, histidine, O-benzylserine, or is absent; and

wherein one or more hydrogen atoms are replaced by deuterium.

2. The compound of claim 1 , wherein aa 1 is valine and aa 2 is absent.

3. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier.

4. A compound having the structural formula:

wherein one or more hydrogen atoms are replaced by deuterium.

5. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5 in a form suitable for oral administration.

7. The pharmaceutical composition of claim 6 , which is in the form of a hard shell gelatin capsule, soft shell gelatin capsule, cachet, pill, tablet, lozenge, powder, granule, pellet, dragee, each of which is optionally enteric coated; a solution; an aqueous liquid suspension; a non-aqueous liquid suspension; an oil-in-water liquid emulsion; a water-in-oil liquid emulsion; an elixir; a syrup; or a pastille.

8. The pharmaceutical composition of claim 7 , which is in the form of a hard shell gelatin capsule, soft shell gelatin capsule, or an enterically coated capsule.

Assignments (7)
CHANGE OF NAME Recorded Jul 9, 2020
From: NEUROCHEM (INTERNATIONAL) LIMITED
To: BELLUS HEALTH (INTERNATIONAL) LIMITED
Reel/Frame 053180/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: THALLION PHARMACEUTICALS INC.
To: BELLUS HEALTH INC.
Reel/Frame 052772/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: BHI LIMITED PARTNERSHIP
To: THALLION PHARMACEUTICALS INC.; BELLUS HEALTH INC.
Reel/Frame 052772/0030 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: KONG, XIANQI; ATFANI, MOHAMED; BACHAND, BENOIT; BOUZIDE, ABDERRAHIM; CIBLAT, STEPHANIE; LEVESQUE, SOPHIE; MIGNEAULT, DAVID; VALADE, ISABELLE; WU, XINFU; DELORME, DANIEL
To: NEUROCHEM (INTERNATIONAL) LIMITED
Reel/Frame 052771/0858 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: BELLUS HEALTH (INTERNATIONAL) LIMITED
To: BELLUS HEALTH INC.
Reel/Frame 052772/0063 →
CHANGE OF NAME Recorded May 28, 2020
From: NEUROCHEM (INTERNATIONAL) LIMITED
To: BELLUS HEALTH (INTERNATIONAL) LIMITED
Reel/Frame 053325/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: BELLUS HEALTH INC.
To: BHI LIMITED PARTNERSHIP
Reel/Frame 052772/0051 →
Continuity (7)
Continuation 16276941 · Feb 15, 2019
Continuation 15293965 · Oct 14, 2016
Continuation 14246894 · Apr 7, 2014
Continuation 11871639 · Oct 12, 2007
Provisional Application 60911459 · Apr 12, 2007
Provisional Application 60851039 · Oct 12, 2006
Related Publication 20200253897A1 · Aug 13, 2020
Cited By (1)
US 12,403,129